Bristol-Myers Squibb CoHere is the public summary page for Bristol-Myers Squibb Co. Please login to see the complete information for Bristol-Myers Squibb Co including detailed analysis of price, sentiment, fundamentals, flow, forecast models, alerts and much more. Also you can see how Bristol-Myers Squibb Co stacks up relative to its peers. |
| Darwin Score | +6 |
| Ticker | BMY |
| Latest Price | 47.17 USD as of close on 16-Jul-2025 |
| 3 Month price range | 43.55 to 50.03 USD |
| Market Capitalisation | 94.49Bn USD |
| Country | United States of America |
| Region | North America |
| Economic Sector | Health Care |
| Business Sector | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Sub-Industry | Pharmaceuticals |
| Description | Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. See More ... |
| Company URL | https://www.bms.com |
| See Darwins Full Analysis for Bristol-Myers Squibb Co |
Tell Me About
Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Bristol-Myers Squibb Co. Further information and full detail is available when you login.
| TMA Part | Focus of Analysis | TMA Score |
|---|---|---|
| Price | Analysis of performance, trend, RSI, OBV and moving averages | +3 |
| Sentiment | News and Candle Patterns. | +1 |
| Fundamentals | Analyst Ratings, Valuation and Dividend analysis. | +2 |
| Flow | Institutional, Fund and Insider buying and selling. | +2 |
| Models | Forecast models. | -2 |
Alerts
There are 7 live alerts for Bristol-Myers Squibb Co.
- Divergence: Px Down & OBV Up last 65 days. This alert has occurred 72 times over the last last year. The average forward returns are 1.1% over 5 days, 2.0% over 10 days, 2.9% over 15 days and 3.0% over 20 days. (Positive)
- Cross Over (Up): 20dma . This alert has occurred 15 times over the last last year. The average forward returns are -0.1% over 5 days, 3.2% over 10 days, 3.8% over 15 days and 4.4% over 20 days. (Positive)
- Divergence: Px Down & 15d RSI Up last 20 days. This alert has occurred 26 times over the last last year. The average forward returns are 0.1% over 5 days, 1.5% over 10 days, 2.2% over 15 days and 1.6% over 20 days. (Positive)
- Divergence: Px Down & OBV Up last 20 days. This alert has occurred 90 times over the last last year. The average forward returns are 0.5% over 5 days, 1.6% over 10 days, 2.4% over 15 days and 2.1% over 20 days. (Positive)
- Divergence: Px Up & 5d RSI Down last 10 days. This alert has occurred 46 times over the last last year. The average forward returns are 0.5% over 5 days, 0.1% over 10 days, 0.6% over 15 days and 1.1% over 20 days. (Negative)
- Divergence: Px Down & 30d RSI Up last 20 days. This alert has occurred 24 times over the last last year. The average forward returns are 1.3% over 5 days, 4.0% over 10 days, 5.6% over 15 days and 4.9% over 20 days. (Positive)
- Cross Over (Up): 50dma . This alert has occurred 5 times over the last last year. The average forward returns are 0.8% over 5 days, 3.3% over 10 days, 2.5% over 15 days and 3.8% over 20 days. (Positive)
Peer Comparison
There are 7 peers of Bristol-Myers Squibb Co.
| Asset Name | Industry Group | Asset Score |
|---|---|---|
| Eli Lilly and Co (LLY) | Pharmaceuticals | +1 |
| Johnson & Johnson (JNJ) | Pharmaceuticals | +29 |
| Merck & Co Inc (MRK) | Pharmaceuticals | +21 |
| Organon & Co (OGN) | Pharmaceuticals | -17 |
| Pfizer Inc (PFE) | Pharmaceuticals | -11 |
| Prestige Consumer Healthcare Inc (PBH) | Pharmaceuticals | +23 |
| Zoetis Inc (ZTS) | Pharmaceuticals | -2 |
Share 
